Predictive Value of Copeptin in the Diagnosis of Acute Ischemic Stroke

Cerebral Vascular Accident (CVA) Clinical Trial

Official title: Predictive Value of Copeptin in the Diagnosis of Acute Ischemic Stroke

Status Completed

Clinical Trial Summary

In the USA, every year 795,000 patients suffer a cerebral vascular accident (CVA), which represents a yearly cost of $73.7 billion. CVA is the third main cause of death and the main source of acquired handicap in adults, as a result it is now a key priority in public health and part of " The CVA National Action Plan 2013-2014".

Copeptin is a polypeptide, by- product of Vasopressin metabolism. The increase of Copeptin plasma level, as for Vasopressin, is connected to hydric balance disorders found in cardio-vascular, renal and endocrine diseases. This link has already shown its interest in the early diagnosis of myocardial infarction and, in a more indirect way, CVA.

Copeptin is associated with acute endogenous stress. It seems to have interesting potential in the diagnosis of CVA by its negative predictive value like D-dimeres in pulmonary embolism. Proadrenomedullin and Brain Natriuretic Peptide (BNP) are both associated with the prognosis of cardio-vascular diseases and could be interesting in evaluating CVA prognosis.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Cerebral Vascular Accident (CVA)
• Stroke

• NCT number: NCT01960478
• Study type: Interventional
• Source: University Hospital, Strasbourg, France
• Status: Completed
• Phase: N/A
• Start date: January 7, 2014
• Completion date: October 5, 2014